November 23, 2016 - By Michael Collier
Mizuho Securities lowered Valeant Pharmaceuticals (NYSE:VRX)‘s stock to a “Underperform” rating from “Neutral”. The ratings change was revealed in a analysts note today. The firm now has a $11.00 target price per share on the stock.
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 2 “Sell”, while 13 “Hold”. This means 35% are positive. $310 is the highest target while $23 is the lowest. The $107.53 average target is 535.90% above today’s ($16.91) stock price. Valeant Pharmaceuticals Intl has been the topic of 79 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was maintained by Scotia Capital with “Sector Outperform” on Tuesday, October 20. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Sector Perform” rating by IBC on Tuesday, October 20. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Neutral” rating by Nomura on Wednesday, March 16. The firm has “Buy” rating given on Monday, April 11 by Rodman & Renshaw. The company was maintained on Monday, November 2 by Jefferies. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Neutral” rating by Mizuho on Friday, October 9. The stock has “Neutral” rating given by Mizuho on Thursday, January 7. The company was reinitiated on Wednesday, January 6 by Susquehanna. The firm earned “Overweight” rating on Thursday, November 10 by Morgan Stanley. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Underperform” rating given on Friday, February 19 by Wells Fargo.
About 11.24 million shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 46.54% since April 21, 2016 and is downtrending. It has underperformed by 51.87% the S&P500.
Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.02, from 0.86 in 2016Q1. The ratio increased, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Conning has 109,769 shares for 0.09% of their US portfolio. Citigroup holds 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 285,091 shares. Duncker Streett & Inc accumulated 200 shares or 0% of the stock. Fosun International Ltd has invested 0.52% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Tci Wealth Advsrs holds 113 shares or 0% of its portfolio. State Street Corp owns 161,545 shares or 0% of their US portfolio. First Western Mgmt Co reported 32,615 shares or 0.24% of all its holdings. Alyeska Inv Group Inc Ltd Partnership last reported 2.84 million shares in the company. Reilly Advisors holds 0% or 70 shares in its portfolio. The Illinois-based Envestnet Asset Mgmt has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Jpmorgan Chase owns 762,998 shares or 0% of their US portfolio. Pcj Invest Counsel last reported 10,000 shares in the company. Sandy Spring Savings Bank reported 306 shares or 0% of all its holdings. Morgan Stanley owns 1.75M shares or 0.01% of their US portfolio. Connor Clark And Lunn Invest Mgmt Limited last reported 1.89M shares in the company.
Insider Transactions: Since June 9, 2016, the stock had 2 insider purchases, and 0 sales for $5.04 million net activity. KARABELAS ARGERIS N bought 4,000 shares worth $98,600. The insider PAPA JOSEPH C bought $4.94 million.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $5.61 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Business.Financialpost.com which released: “Valeant Pharmaceuticals International Inc downgraded again” on November 23, 2016, also Fool.ca with their article: “Will Canopy Growth Corp. Crash as Hard as Valeant Pharmaceuticals Intl Inc.?” published on November 23, 2016, Business.Financialpost.com published: “Valeant Pharmaceuticals International needs to do a lot more than just cry …” on November 21, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Fool.com and their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” with publication date: November 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.